CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-16 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,300 | $194.17 | $447K | 2,357,172 |
| 2026-03-16 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −4,875 | $195.42 | $953K | 2,352,297 |
| 2026-03-16 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −24,814 | $196.23 | $4.9M | 2,327,483 |
| 2026-03-16 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −16,457 | $197.22 | $3.2M | 2,311,026 |
| 2026-03-16 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −254 | $198.02 | $50K | 2,310,772 |
| 2026-03-16 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Option exercise · Stock Option (right to buy) 10b5-1 | −50,000 | 100,000 | ||
| 2026-03-13 | Chapman Rowan E Director | Sale 10b5-1 | −122 | $191.38 | $23K | 5,752 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Option exercise 10b5-1 | +75,000 | $9.59 | $719K | 2,385,772 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −17,037 | $187.63 | $3.2M | 2,368,735 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −21,476 | $188.54 | $4.0M | 2,347,259 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −21,504 | $189.50 | $4.1M | 2,325,755 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −13,883 | $190.46 | $2.6M | 2,311,872 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,100 | $191.22 | $210K | 2,310,772 |
| 2026-03-13 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Option exercise · Stock Option (right to buy) 10b5-1 | −75,000 | 150,000 | ||
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Option exercise 10b5-1 | +75,000 | $9.59 | $719K | 2,385,772 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −8,091 | $186.75 | $1.5M | 2,377,681 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,809 | $187.52 | $1.1M | 2,371,872 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −6,451 | $188.52 | $1.2M | 2,365,421 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,886 | $189.64 | $547K | 2,362,535 |
| 2026-03-12 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −22,063 | $190.53 | $4.2M | 2,340,472 |
Page 23 of 39 · 767 trades